RenovoRx, Inc. (RNXT) Research

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

Market snapshot

Symbol
RNXT
Price
$0.92
Day change
+3.29%
Market cap
$34.2M
P/E ratio
-2.85x
52-week range
0.701-1.45
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Annovis Bio, Inc. (ANVS)
  • BioAtla, Inc. (BCAB)
  • CalciMedica, Inc. (CALC)
  • Celularity Inc. (CELU)
  • Elutia Inc. (ELUT)
  • Lantern Pharma Inc. (LTRN)
  • MAIA Biotechnology, Inc. (MAIA)
  • PolyPid Ltd. (PYPD)

Recent insider activity

  • VOLL MARK — P-Purchase (25000 shares) on 2026-05-19
  • Bagai Shaun — A-Award (946107 shares) on 2026-04-03
  • VOLL MARK — A-Award (80000 shares) on 2026-04-03
  • Gentry Leesa — A-Award (128550 shares) on 2026-04-03
  • Agah Ramtin — A-Award (621727 shares) on 2026-04-03

Open RenovoRx, Inc. (RNXT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.